Arcadia Biosciences Inc (NASDAQ:RKDA) CEO Matthew T. Plavan acquired 2,000 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was purchased at an average cost of $6.51 per share, with a total value of $13,020.00. Following the completion of the acquisition, the chief executive officer now owns 9,000 shares of the company’s stock, valued at $58,590. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
NASDAQ:RKDA opened at $5.68 on Friday. The firm has a market capitalization of $46.26 million, a PE ratio of -1.06 and a beta of -2.94. The stock has a 50 day moving average of $5.35 and a 200-day moving average of $5.37. Arcadia Biosciences Inc has a 52 week low of $1.82 and a 52 week high of $10.40. The company has a current ratio of 5.29, a quick ratio of 5.09 and a debt-to-equity ratio of 0.19.
Several analysts recently weighed in on RKDA shares. ValuEngine lowered Arcadia Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, August 15th. National Securities boosted their price objective on Arcadia Biosciences from $12.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, August 15th. Finally, HC Wainwright reissued a “buy” rating on shares of Arcadia Biosciences in a report on Monday, August 12th.
Arcadia Biosciences Company Profile
Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.
Featured Article: LIBOR
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.